Watsco, Inc. WSO has been benefiting from ongoing investment in technology, higher HVAC equipment unit growth, and improved equipment pricing and sales mix. However, higher SG&A expenses and seasonal factors raise concerns.
Last month, the company reported fourth-quarter 2018 results, wherein earnings and revenues missed the Zacks Consensus Estimate by 3.8% and 1.9%, respectively. The poor performance was mainly due to extreme weather conditions and certain incremental costs.
Nonetheless, earnings and revenues increased 13.3% and 2.8%, respectively, from the year-ago level. The upside stemmed from higher unit demand in HVAC equipment, and improved pricing and sales mix. Continued investment in the technologies designed to revolutionize customer experience added to the positives.
Key Growth Drivers
Watsco has been investing in technology to improve customer experience through e-commerce, in a bid to improve speed, productivity and efficiency. Given the use of various technology platforms, the company’s e-commerce sales accounted for 29% of the total sales in 2018 compared with 25% a year ago.
It is poised to benefit from strong unit demand, higher pricing and sales mix. Sales of HVAC equipment (heating, ventilating and air conditioning; comprising 67% of sales) grew 6% in 2018, and that of other HVAC products (29% of sales) increased 5% from a year ago.
Watsco’s acquisition of Alert Labs, a technology company in Canada, in October 2018 will help it to grow its customer base and profitability. The buyout will also help the company in leveraging technology investment, enhancing productivity and reducing costs.
Meanwhile, consistent dividend payouts underscore the company’s financial strength and stability. During the fourth quarter, Watsco raised its annual dividend by 10% to $6.40 per share. Notably, 2018 marked the 45th consecutive year of dividend payment by Watsco.
Since 2000, the company’s cash flow was approximately $2.4 billion and net income totaled roughly $2.3 billion, meeting its stated goal of generating cash flow in excess of net income. The company continues to look for investments to grow network, and invest in acquisitions or mergers. Notably, it generated a 30-year compounded total shareholder return of 18%.
Shares of Watsco have lost 18.4% against its industry's growth of 3.7% in the past year. Earnings estimates for 2019 and 2020 have declined 0.7% and 0.4%, respectively, over the past 30 days, depicting analysts’ concern surrounding the company's bottom-line growth potential.
Higher SG&A expenses, lower vendor incentives and seasonal factors are pressing concerns for Watsco. The company’s digitization of business and incremental technology spending have been substantially increasing SG&A expenses over the past few years. In fact, incremental SG&A, which includes $9 million in field-level incentive compensation, $7 million in health-related costs and $4 million in incremental technology spending (including the acquisition of Alert Labs), impacted overall performance of the company in 2018.
Also, fluctuations in sales due to seasonal demand of residential air conditioners and heating equipment significantly hurt its profitability. Watsco’s profitability will be impacted favorably or unfavorably, based on the severity or mildness of weather patterns during summer or winter selling seasons.
Zacks Rank & Stocks to Consider
Watsco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the Zacks Construction sector include Quanta Services, Inc. PWR, Apergy Corp. APY, and Armstrong World Industries, Inc. AWI. While Quanta Services and Apergy sport a Zacks Rank #1 (Strong Buy), Armstrong World carries a Zacks Rank #2 (Buy).
Quanta Services and Armstrong World’s earnings for the next year are expected to increase 4.3% and 12.6%, respectively.
Apergy has a solid three-five year expected EPS growth rate of 22.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Armstrong World Industries, Inc. (AWI) : Free Stock Analysis Report
Watsco, Inc. (WSO) : Free Stock Analysis Report
Quanta Services, Inc. (PWR) : Free Stock Analysis Report
Apergy Corporation (APY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research